TEIM-060-039C CTR Sign-Off Sheet

CLINICAL TRIAL REPORT SIGN-OFF SHEET

Trial title: A multi-site, Phase III, 2-part, dose-escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2-RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults

Trial number: BNT162-01
Report type: Interim
Report version/Date: 3.0 / 20 March 2021

Name, role, affiliation

Sponsor signatories

Elizabeth Adams, MD, Senior Medical Director, BioNTech US, Inc.

Stefan Liebscher, PhD, MSc
Responsible Statistician,
Dr Liebscher Consulting, Germany

Date (DD MMM YYYY) Signature (Hand written)
21 Mar 2021

The sponsor signatories confirm that this report i) has been prepared, reviewed, and approved in accordance with the sponsor’s standard operating procedures, ii) that the report is accurate, scientifically sound, and adequately presents all relevant information, iii) that documentation of this process is filed in the trial master file, and iv) that they approve the document.

Coordinating investigator

Dr. Dr. med. Armin Schultz,
CRS Clinical Research Services
Mannheim GmbH, Germany

The coordinating investigator confirms i) that he has reviewed the report, ii) that the report is accurate, scientifically sound, and adequately presents all relevant information, and iii) that he approves the document.
Clinical Trial Report Sign-Off Sheet

Trial title: A multi-site, Phase III, 2-part, dose-escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults

Trial number: BNT162-01

Report type: Interim

Report version/Date: 3.0 / 20 March 2021

Name, role, affiliation

Sponsor signatories

Elizabeth Adams, MD, Senior Medical Director, BioNTech US, Inc.

Date (DD MMM YYYY)  Signature (Handwritten)

Stefan Liebscher, PhD, MSc
Responsible Statistician,
Dr Liebscher Consulting, Germany

21 MAR 2021  S. Liebscher

The sponsor signatories confirm that this report i) has been prepared, reviewed, and approved in accordance with the sponsor’s standard operating procedures, ii) that the report is accurate, scientifically sound, and adequately presents all relevant information, iii) that documentation of this process is filed in the trial master file, and iv) that they approve the document.

Coordinating investigator

Dr. Dr. med. Armin Schultz,
CRS Clinical Research Services
Mannheim GmbH, Germany

The coordinating investigator confirms i) that he has reviewed the report, ii) that the report is accurate, scientifically sound, and adequately presents all relevant information, and iii) that he approves the document.